Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers

Cybin D/B/A Helus Pharma (NASDAQ:HELP) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds.

The seventh stock on our list of most promising stocks is Cybin D/B/A Helus Pharma (NASDAQ:HELP).

TheFly reported on February 2 that Jefferies initiated coverage of HELP with a Buy rating and a $22 price target and also highlighted significant upside potential. The firm has identified three key catalysts for 2026 which includes the recent appointment of a permanent CEO, which is seen as a crucial operational and strategic milestone supporting stock appreciation; the lead asset, HLP003, an oral d-psilocin therapy for adjunct major depressive disorder, has a roughly 60% probability of success in its Phase III trial, which could drive a 100%-200% share rally; and HLP004, an intramuscular d-DMT therapy, is anticipated to report de-risking Phase II data in Q1.

Furthermore, Cybin D/B/A Helus Pharma (NASDAQ:HELP) announced Q3 fiscal 2026 results on February 13 for the quarter that concluded on December 31, 2025, showing $195.1 million in cash on hand before any post-quarter adjustments. To advance a multi-asset neuroscience portfolio throughout many stages of development, the business placed a strong emphasis on maintaining disciplined execution across its clinical and operational priorities. The HLP003 Phase 3 and HLP004 Phase 2 studies are still making progress, with an emphasis on clinical strategies that are repeatable and scalable. HELP is well-positioned to deliver on future clinical milestones and generate long-term shareholder value thanks to its solid balance sheet and continuous clinical advances.

Cybin D/B/A Helus Pharma (NASDAQ:HELP) is a clinical‑stage psychedelic biotechnology company developing innovative psilocybin‑based and novel psychotherapeutic compounds and delivery systems to treat mental health conditions with science‑driven, evidence‑based approaches.

While we acknowledge the potential of HELP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.

Disclosure: None.